“The insurance benefit of Velcade as the primary treatment is urgently required”
An opinion was stressed again that the insurance benefit of ‘Velcade(generic name: bortezomib)’ needs to be extended for multiple myeloma patients to use as the primary treatment.
On the 22nd, Prefessor Jae-joong Lee of the department of internal medicine, Chonnam National University Hwasun Hosp...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
